drugset / Trial / NCT04782089
Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer
Unknown
20 enrolled
Qilu Hospital of Shandong University
Jiangsu HengRui Medicine Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase II, Open, Single-center Study of Camrelizumab and Fluzoparib as Consolidation Treatment for Patients With Extensive stage small cell lung cancer Who Have Not Progressed after first-line treatment
Timeline
- Start
- 2021-05-06
- Primary completion
- 2023-05-01
- Completion
- 2024-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | — | — |
| Subject | Fluzoparib | Small molecule | — | — |